185 related articles for article (PubMed ID: 20871013)
1. A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.
Bedia C; Camacho L; Abad JL; Fabriàs G; Levade T
J Lipid Res; 2010 Dec; 51(12):3542-7. PubMed ID: 20871013
[TBL] [Abstract][Full Text] [Related]
2. Systemic ceramide accumulation leads to severe and varied pathological consequences.
Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
[TBL] [Abstract][Full Text] [Related]
3. Acid ceramidase deficiency: Farber disease and SMA-PME.
Yu FPS; Amintas S; Levade T; Medin JA
Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
[TBL] [Abstract][Full Text] [Related]
4. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
[TBL] [Abstract][Full Text] [Related]
5. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
[TBL] [Abstract][Full Text] [Related]
6. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
[TBL] [Abstract][Full Text] [Related]
7. Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.
Yu FPS; Dworski S; Medin JA
Sci Rep; 2018 Jan; 8(1):1808. PubMed ID: 29379059
[TBL] [Abstract][Full Text] [Related]
8. Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency.
Rybova J; Kuchar L; Sikora J; McKillop WM; Medin JA
J Inherit Metab Dis; 2022 Nov; 45(6):1175-1190. PubMed ID: 36083604
[TBL] [Abstract][Full Text] [Related]
9. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
[TBL] [Abstract][Full Text] [Related]
12. Pathological manifestations of Farber disease in a new mouse model.
Beckmann N; Kadow S; Schumacher F; Göthert JR; Kesper S; Draeger A; Schulz-Schaeffer WJ; Wang J; Becker JU; Kramer M; Kühn C; Kleuser B; Becker KA; Gulbins E; Carpinteiro A
Biol Chem; 2018 Sep; 399(10):1183-1202. PubMed ID: 29908121
[TBL] [Abstract][Full Text] [Related]
13. Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency.
Yu FPS; Molino S; Sikora J; Rasmussen S; Rybova J; Tate E; Geurts AM; Turner PV; Mckillop WM; Medin JA
Lab Invest; 2019 Oct; 99(10):1572-1592. PubMed ID: 31186526
[TBL] [Abstract][Full Text] [Related]
14. Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.
Jenkins RW; Clarke CJ; Canals D; Snider AJ; Gault CR; Heffernan-Stroud L; Wu BX; Simbari F; Roddy P; Kitatani K; Obeid LM; Hannun YA
J Biol Chem; 2011 Apr; 286(15):13292-303. PubMed ID: 21335555
[TBL] [Abstract][Full Text] [Related]
15. Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.
Bai A; Bielawska A; Rahmaniyan M; Kraveka JM; Bielawski J; Hannun YA
Bioorg Med Chem; 2018 Dec; 26(23-24):6067-6075. PubMed ID: 30448190
[TBL] [Abstract][Full Text] [Related]
16. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
Dworski S; Lu P; Khan A; Maranda B; Mitchell JJ; Parini R; Di Rocco M; Hugle B; Yoshimitsu M; Magnusson B; Makay B; Arslan N; Guelbert N; Ehlert K; Jarisch A; Gardner-Medwin J; Dagher R; Terreri MT; Lorenco CM; Barillas-Arias L; Tanpaiboon P; Solyom A; Norris JS; He X; Schuchman EH; Levade T; Medin JA
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):386-394. PubMed ID: 27915031
[TBL] [Abstract][Full Text] [Related]
17. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.
Cozma C; Iurașcu MI; Eichler S; Hovakimyan M; Brandau O; Zielke S; Böttcher T; Giese AK; Lukas J; Rolfs A
Sci Rep; 2017 Jul; 7(1):6149. PubMed ID: 28733637
[TBL] [Abstract][Full Text] [Related]
18. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
[TBL] [Abstract][Full Text] [Related]
19. Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.
Mizutani N; Inoue M; Omori Y; Ito H; Tamiya-Koizumi K; Takagi A; Kojima T; Nakamura M; Iwaki S; Nakatochi M; Suzuki M; Nozawa Y; Murate T
J Biochem; 2015 Oct; 158(4):309-19. PubMed ID: 25888580
[TBL] [Abstract][Full Text] [Related]
20. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
